The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC Sept 2021 | Pralsetinib in Chinese patients with advanced RET fusion+ NSCLC
Qing Zhou, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, describes a cohort analysis presented at the World Conference on Lung Cancer (WCLC) 2021, from the global Phase I/II ARROW study (NCT03037385) of pralsetinib, a highly potent and selective RET kinase inhibitor. The analysis demonstrates that first line pralsetinib therapy induces rapid, durable tumor responses and a well-tolerated safety profile in Chinese patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC). Dr Zhou proposes that pralsetinib represents a promising first line treatment option for Chinese patients with RET-fusion driven advanced NSCLC. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.
